Digestive Endoscopy Center, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
Department of Gastroenterology, First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
J Gastroenterol Hepatol. 2021 Jun;36(6):1508-1517. doi: 10.1111/jgh.15369. Epub 2021 Jan 5.
Dysbiosis in the gut microbiota composition due to environmental or genetic variations can disrupt the immune system and may promote several diseases such as colorectal cancer (CRC). Gut microbiota can alter the toxicity and efficiency of an extensive range of CRC treatment methods, especially surgery, chemotherapy, radiotherapy, and immunotherapy. The recent scientific evidence suggested that gut microbiota modulation exhibits an essential positive influence on inhibition and treatment of CRC. The literature survey revealed that modulating the gut microbiota composition by probiotics, prebiotics, and diets protects CRC patients from treatment-associated adverse effects. This review summarizes the recent advancements in the association between interventions on gut microbiota and CRC to provide innovative strategies for enhancing the safety and efficiency of CRC therapy.
由于环境或遗传变异导致的肠道微生物群落组成失调会破坏免疫系统,并可能促进多种疾病的发生,如结直肠癌(CRC)。肠道微生物群落可以改变广泛的 CRC 治疗方法的毒性和效率,特别是手术、化疗、放疗和免疫疗法。最近的科学证据表明,肠道微生物群落的调节对抑制和治疗 CRC 具有重要的积极影响。文献调查显示,通过益生菌、益生元和饮食来调节肠道微生物群落组成,可以保护 CRC 患者免受治疗相关的不良反应。本综述总结了肠道微生物群与 CRC 之间干预措施的最新进展,为提高 CRC 治疗的安全性和效率提供了创新策略。